A phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathologic complete response at surgery.

Authors: Heather L. McArthur, Rebecca Alexandra Dent, Rina Hui, Yeon Hee Park, Peter Schmid, Jing Wei, Jaime A. Mejia, Wilbur Pan, Javier Cortes

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps616

Source: Full article

TPS616